跳至主要内容
临床试验/NCT00768040
NCT00768040终止2 期

A Randomized, Double-masked, Placebo-controlled, add-on Study to Assess the Efficacy of Oral Aliskiren 300 mg Once Daily for Diabetic Macular Edema

Novartis Pharmaceuticals11 个研究点 分布在 2 个国家目标入组 39 人开始时间: 2008年9月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
终止
入组人数
39
试验地点
11
主要终点
Change From Baseline in Central Retinal Thickness in Patients With Type 1 or Type 2 Diabetes, After 12 Weeks of Treatment

研究概览

简要总结

To assess the efficacy of oral aliskiren as a therapy for diabetic macular edema

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Triple (Participant, Care Provider, Investigator)

入排标准

年龄范围
18 Years 至 85 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

研究组 & 干预措施

Aliskiren 300 mg

Experimental

Aliskiren 300 mg once daily for 12 weeks

干预措施: Aliskiren (Drug)

Placebo

Placebo Comparator

Matching placebo once daily for 12 weeks

干预措施: Placebo (Drug)

结局指标

主要结局

Change From Baseline in Central Retinal Thickness in Patients With Type 1 or Type 2 Diabetes, After 12 Weeks of Treatment

时间窗: Baseline to week 12

The central retinal thickness was measured by Optical coherence tomography (OCT). The changes in central retinal thickness (CRT) from baseline to the end of study at week 12 were analyzed using a univariate analysis of covariance model (ANCOVA) with baseline value as a covariate and treatment as a fixed factor

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (11)

Loading locations...

相似试验